Immunotherapy | Clinical

July 01, 2022

During a case-based roundtable event, Joshua K. Sabari, MD, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer.

June 29, 2022

Kruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.

June 24, 2022

A retrospective analysis of next-generation sequencing data showed that the presence of pathogenic POLE mutations correlate with clinical benefit in immune checkpoint inhibitor therapy.

June 23, 2022

David L. Bartlett, MD, discussed the adoption of key immunotherapies and how exploration of the tumor microenvironment and immune environment is opening new approaches to treatment in an interview with Targeted Oncology.

June 19, 2022

The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.

June 17, 2022

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

June 15, 2022

Most studies of how timing affects immunotherapy efficacy have defined “timing” relative to other treatments, but some research has investigated the impact of giving patients immunotherapy at different times of day.

May 06, 2022

The first patient has been enrolled into the PREMIER registry for patients with all stages of cancer.

May 05, 2022

In an interview with Targeted Oncology, Robert Sackstein, MD, discussed ongoing research around the strategy of targeting the sugar coat of cancer cells to potentially aid in cancer treatment, particularly in hematologic malignancies.

May 04, 2022

Florida Cancer Specialists & Research Institute sites and site worldwide are now recruiting patients for the PROPHETIC study.